Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

IMMUNOGEN, INC. (IMGN)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/18 10:00:00 pm
10.61 USD   -1.39%
05/17IMMUNOGEN,INC. : IMGN) Files An 8-K Other Events
AQ
05/16IMMUNOGEN : Announces Positive Findings from the FORWARD II Study of..
BU
05/04IMMUNOGEN : 1Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201420152017201820192020
Sales59,985,511564,181,6105
EBITDA-66,9-54,4-53,0-135-116-157
Operating profit (EBIT)-71,5-59,9-59,0-140-125-138
Pre-Tax Profit (EBT)------
Net income-71,4-60,7-96,0-151-135-142
P/E ratio-7,35-19,1-6,54-9,45-11,2-10,9
EPS ( $ )-0,83-0,71-0,98-1,12-0,95-0,97
Dividend per Share ( $ )------
Yield------
Reference price ( $ )6.113.576.4110.6110.6110.61
Announcement Date08/01/2014
10:30am
07/31/2015
10:30am
02/09/2018
11:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201420152017201820192020
Debt------
Finance142278267-13324,3
Operating income (EBITDA)-66,9-54,4-53,0-135-116-157
Leverage
(Debt/EBITDA)
------
Capital Expenditure8,187,431,125,064,438,16
Book Value Per Share (BVPS)0,88 $0,41 $-0,15 $-0,33 $-0,37 $-0,78 $
Cash Flow per Share-0,63 $-0,64 $0,08 $-1,15 $-0,78 $-
Announcement Date08/01/2014
10:30am
07/31/2015
10:30am
02/09/2018
11:30am
---
Balance Sheet Analysis
Assessed data source :
© 2018 Thomson Reuters
Financial Ratios

Size 2018e 2019e
Capitalization 1 431 M$ -
Entreprise Value (EV) - 1 298 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS)
Capitalization / Revenue 22,3x 17,5x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) - -
Price to book (Price / BVPS) -32,5x -28,7x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) -218% -153%
operating Leverage (Delta EBIT / Delta Sales) -3,07x 0,39x
Net Margin (Net Profit / Revenue) -236% -166%
ROA (Net Profit / Asset) -60,6% -56,4%
ROE (Net Profit / Equities) 93,8% 164%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   7,89% 5,43%
Cash Flow / Sales -239% -127%
Capital Intensity (Assets / Sales) 3,89x 2,94x
Financial Leverage (Net Debt / EBITDA) - 1,15x
EPS & Dividend